Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Oncotarget - 6 Jun 2017

Mairinger Fabian Dominik, Vollbrecht Claudia, Flom Elena, Christoph Daniel Christian, Schmid Kurt-Werner, Kollmeier Jens, Popper Helmut Hans, Mairinger Thomas, Walter Robert Fred Henry

Abstract excerpt

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a remission-rate of only about 40%. The reasons for the rather poor efficacy remain largely unknown. RESULTS: Phenotypes were significantly associated with progression (p=0.0279) and remission (p=0.0262). Cox-regression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Folic Acid
Share to Mesothelioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mesothelioma, Malignant

Share to Pemetrexed

Share to Peptide Synthases

Share to Pleural Neoplasms

Share to Reduced Folate Carrier Protein

Share to Thymidylate Synthase

Source

Open in PubMed Open full text

Identifiers

PMID: 28415584
DOI: 10.18632/oncotarget.16398
PMCID: PMC5514925

Genes

TYMS
FAP
FPGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.PMID 28415584Read ↗

Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.Semantic proximity Read ↗

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Progress and challenges in Mesothelioma: From bench to bedside.Semantic proximity Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological toolsSemantic proximity Read ↗

Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.Semantic proximity Read ↗

Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancerSemantic proximity Read ↗

Molecular Mechanism of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in MesotheliomaSemantic proximity Read ↗

Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study.Semantic proximity Read ↗

Integrated genomics point to immune vulnerabilities in pleural mesothelioma.Semantic proximity Read ↗

Folate Metabolism in Colorectal Cancer Reveals Links Between Clinical and Immune Traits, Identifying CYP26A1 as a TargetSemantic proximity Read ↗

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of MesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.